<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Patient-derived <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft models</z:e> are considered to represent the <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> of human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> and advanced preclinical models </plain></SENT>
<SENT sid="1" pm="."><plain>Our consortium joins efforts to extensively develop and characterize a new collection of patient-derived <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) models </plain></SENT>
<SENT sid="2" pm="."><plain>EXPERIMENTAL DESIGN: From the 85 unsupervised surgical colorectal samples collection, 54 tumors were successfully xenografted in immunodeficient mice and rats, representing 35 primary <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, 5 peritoneal carcinoses and 14 metastases </plain></SENT>
<SENT sid="3" pm="."><plain>Histologic and molecular characterization of patient <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, first and late passages on mice includes the sequence of key genes involved in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> (i.e., APC, KRAS, TP53), aCGH, and transcriptomic analysis </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: This comprehensive characterization shows that our collection recapitulates the clinical situation about the histopathology and molecular diversity of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Moreover, patient <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and corresponding models are clustering together allowing comparison studies between clinical and preclinical data </plain></SENT>
<SENT sid="6" pm="."><plain>Hence, we conducted pharmacologic monotherapy studies with standard of care for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> (<z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi>, <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>, irinotecan, and cetuximab) </plain></SENT>
<SENT sid="7" pm="."><plain>Through this extensive in vivo analysis, we have shown the loss of human stroma cells after engraftment, observed a metastatic phenotype in some models, and finally compared the molecular profile with the drug sensitivity of each <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> model </plain></SENT>
<SENT sid="8" pm="."><plain>Through an experimental cetuximab phase II trial, we confirmed the key role of KRAS mutation in cetuximab resistance </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: This new collection could bring benefit to evaluate novel targeted therapeutic strategies and to better understand the basis for sensitivity or resistance of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> from individual patients </plain></SENT>
</text></document>